Drugs Made In America Acquisition II Corp. (DMIIR)
Drugs Made In America Acquisition II Corp. (DMIIR)
Balance Sheets Overview
Current Ratio
33.79%
Quick Ratio
33.79%
Debt to Asset Ratio
3.53%
Unit: Dollar
Assets Breakdown
Cash and investments held in tru...
Cash
Prepaid expenses
Liabilities Breakdown
Ordinary shares subject to possi...
Accumulated deficit
Deferred underwriting fee payabl...
Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
Cash
174,974
347,720
223
Prepaid expenses
42,849
4,041
25,814
Total current assets
217,823
351,761
26,037
Cash and investments held in trust account
513,882,333
509,373,650
504,933,800
Total non-current assets
513,882,333
509,373,650
504,933,800
Total assets
514,100,156
509,725,411
504,959,837
Accounts payable
12,253
49,166
99,359
Accrued expenses
69,159
53,957
88,343
Accrued offering costs
113,162
113,162
113,162
Promissory notes
450,000
450,000
-
Total current liabilities
644,574
666,285
300,864
Deferred underwriting fee payable
17,500,000
17,500,000
17,500,000
Total non-current liabilities
17,500,000
17,500,000
17,500,000
Total liabilities
18,144,574
18,166,285
17,800,864
Ordinary shares subject to possible redemption, 50,000,000 shares at redemption value of 10.28 and 10.10 per share as of june 30, 2026 and december 31, 2025, respectively
513,882,333
509,373,650
504,933,800
Ordinary shares, 0.0001 par value 220,000,000 shares authorized 13,700,000 shares issued and outstanding, excluding 50,000,000 shares subject to redemption as of june 30, 2026 and december 31, 2025
1,369
1,369
1,369
Accumulated deficit
-17,928,120
-17,815,893
-17,776,196
Total shareholders deficit
-17,926,751
-17,814,524
-17,774,827
Total liabilities, ordinary shares subject to possible redemption, and shareholders deficit
514,100,156
509,725,411
504,959,837
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.